Explore / Stock comparison 1 of 3 daily views used · 2 remaining. Refreshes and chart changes do not use another view.
Price Valuation Financials
Daily close · 2026-10-12 Price return Closing price
Quarterly Yearly
Price return Both stocks start at 0% on the first shared trading day.
Price return: BJDX and NXL Historical recorded observations on the same scale. Missing metrics leave gaps. -115% -59% -3% 53% 109% 2022 2023 2024 2025 2025 2026
Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.
Split-adjusted closing prices. Dividends are excluded. Explore stocks within your daily allowance.
Enable JavaScript to change metrics, ranges and fiscal cadence. The initial chart and financial table remain available.
Business overlap Businesses Fundamentals Methodology Similarity 100.0%
4 shared / 4 total tags How similar are their businesses? The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.
Hardware Healthcare Medical Devices Technology
How we measure overlap ↗ The businesses behind the score
Industry overlap Filing-derived business activity overlap Counts of retained positive business classifications. Circle sizes do not encode the counts or the weighted similarity score. BJDX only 0 Shared 4 NXL only 0 BJDX only · 0 No activities in this group.
Shared activities · 4 HardwareBJDX: Material · NXL: Material ↗ Filing evidence HealthcareBJDX: Core · NXL: Core ↗ Filing evidence Medical DevicesBJDX: Core · NXL: Core ↗ Filing evidence TechnologyBJDX: Material · NXL: Material ↗ Filing evidence NXL only · 0 No activities in this group.
Positive activities from the two selected annual filings. Up to six activities per group are shown here; every activity remains in the complete table. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is. Show business activity table · 4 rows, 3 columns All 4 Shared 4 Different 0
Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.
BJDX Material Annual filing released 2025-03-31 · GPT 6 Luna
Bluejay
Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care
settings. We are working on developing rapid tests using whole blood on our Symphony technology platform (“Symphony”),
which consists of an analyzer and single-use cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the “FDA”) to be marketed as a diagnostic
product in the United States. We have completed the development of the Symphony analyzer. We are currently preparing to transfer
the intellectual property underlying the production of the Symphony cartridges from the original developer and outside supplier,
Toray Industries, to an in-house facility. The
Symphony platform is a proprietary technology platform that is designed to provide rapid and accurate measurements of key diagnostic
biomarkers found in blood in a manner that we believe is innovative in the market. Symphony is compact and is designed for the potential
of it to be deployed in a manner that is more mobile than current laboratory diagnostic platforms on the market. Symphony incorporates
a user-friendly interface where all sample preparation and reagents are integrated into the disposable Symphony cartridges. Symphony
only requires a few drops of blood to provide a measurement in approximately 20 minutes. Read the annual filing ↗ NXL Material Annual filing released 2025-03-14 · GPT 6 Luna
Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device. ●
Right to invoice — the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date; the Company may recognize revenue in the amount to which the entity has a right to invoice.
Disaggregated Revenues
Major Revenue Streams
Revenue consists of the following by service offering:
Years Ended
December 31,
2024
2023
Device sales
$
55,500
$
-
Licensing fee
69,501
82,080
Equipment
37,826
27,299
Other
5,894
1,369
Total
$
168,721
$
110,748
Major Geographic Locations
Years Ended
December 31,
2024
2023
U.S. sales
$
83,473
$
107,134
China sales
85,248
3,614
Total
$
168,721
$
110,748 Read the annual filing ↗ BJDX Core Annual filing released 2025-03-31 · GPT 6 Luna
Bluejay
Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care
settings. We are working on developing rapid tests using whole blood on our Symphony technology platform (“Symphony”),
which consists of an analyzer and single-use cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the “FDA”) to be marketed as a diagnostic
product in the United States. We have completed the development of the Symphony analyzer. We are currently preparing to transfer
the intellectual property underlying the production of the Symphony cartridges from the original developer and outside supplier,
Toray Industries, to an in-house facility. Using
the data analysis from the SYMON-I pilot clinical study, we initiated the SYMON-II pivotal clinical study in the third quarter of 2024.
The SYMON II clinical study has three components: (1) collection, freezing, and biobanking of patient samples, (2) measuring IL-6 concentrations
in the biobanked samples near the end of patient enrollment or after the patient enrollment has completed, and (3) analysis of the IL-6
data with the patient outcomes to see if the established IL-6 cutoff value has been validated for 28-day all-cause mortality. Patient
enrollment started during the fourth quarter of 2024. Our goal is to use the Symphony IL-6 test to complete the testing in the SYMON-II
clinical trial. Read the annual filing ↗ NXL Core Annual filing released 2025-03-14 · GPT 6 Luna
Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating and reporting segment, which is the business of designing and developing innovative neurostimulation products.
Recent Accounting Pronouncements Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device. Read the annual filing ↗ BJDX Core Annual filing released 2025-03-31 · GPT 6 Luna
Bluejay
Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care
settings. We are working on developing rapid tests using whole blood on our Symphony technology platform (“Symphony”),
which consists of an analyzer and single-use cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the “FDA”) to be marketed as a diagnostic
product in the United States. We have completed the development of the Symphony analyzer. We are currently preparing to transfer
the intellectual property underlying the production of the Symphony cartridges from the original developer and outside supplier,
Toray Industries, to an in-house facility. Our
first product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring
of disease progression in critical care settings. We are currently focused on pursuing the Symphony IL-6 test in the context of sepsis.
IL-6 is a clinically established inflammatory biomarker, and is considered a ‘first-responder,’ for assessment of severity
of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the
excessive time and cost associated determining a patient’s level of severity at triage and we believe that our Symphony IL-6 test,
if ultimately successful and approved, could have the ability to consistently monitor this critical care biomarker with rapid results. Read the annual filing ↗ NXL Core Annual filing released 2025-03-14 · GPT 6 Luna
Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating and reporting segment, which is the business of designing and developing innovative neurostimulation products.
Recent Accounting Pronouncements Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device. Read the annual filing ↗ BJDX Material Annual filing released 2025-03-31 · GPT 6 Luna
Bluejay
Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care
settings. We are working on developing rapid tests using whole blood on our Symphony technology platform (“Symphony”),
which consists of an analyzer and single-use cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
receive regulatory authorization from the U.S. Food and Drug Administration (the “FDA”) to be marketed as a diagnostic
product in the United States. We have completed the development of the Symphony analyzer. We are currently preparing to transfer
the intellectual property underlying the production of the Symphony cartridges from the original developer and outside supplier,
Toray Industries, to an in-house facility. We
are a clinical-stage medical diagnostics company developing rapid tests using whole blood on our Symphony platform (“Symphony”)
to improve patient outcomes in critical care settings. Our Symphony technology platform is an exclusively licensed, patented system that
consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration
(“FDA”), could provide a solution to a significant market need in the United States. Clinical trials indicate Symphony produces
laboratory-quality results in less than 20 minutes in critical care settings, including Intensive Care Units (“ICUs”) and
Emergency Rooms (“ERs”), where rapid and reliable results are required. Read the annual filing ↗ NXL Material Annual filing released 2025-03-14 · GPT 6 Luna
Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device. ●
Right to invoice — the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date; the Company may recognize revenue in the amount to which the entity has a right to invoice.
Disaggregated Revenues
Major Revenue Streams
Revenue consists of the following by service offering:
Years Ended
December 31,
2024
2023
Device sales
$
55,500
$
-
Licensing fee
69,501
82,080
Equipment
37,826
27,299
Other
5,894
1,369
Total
$
168,721
$
110,748
Major Geographic Locations
Years Ended
December 31,
2024
2023
U.S. sales
$
83,473
$
107,134
China sales
85,248
3,614
Total
$
168,721
$
110,748 Read the annual filing ↗ What each company does Compare the businesses BS
Bluejay Diagnostics, Inc. Common Stock BJDX · XNAS Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Open BJDX dashboard ↗ NS
Nexalin Technology, Inc. Common Stock NXL · XNAS Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Open NXL dashboard ↗ Show fundamentals table · 11 rows, 3 columns USD values from stored observations. Fiscal period endings and availability dates may differ.
BJDX period ended 2025-12-31 · available 2026-03-06 · SEC filing ↗ NXL period ended 2025-12-31 · available 2026-03-25 · SEC filing ↗ Behind the comparison Sources and methodology Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.
Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.
Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.
Related comparisons require a shared specific core activity and at least 20% overlap. Broad categories alone do not establish a close peer relationship. Identical classifications can score 100% even when companies sell different products. We select up to ten leading peers per issuer for discovery, combine both directions, and require current common shares, public company profiles and stored price observations. Arbitrary stock pairs remain available.
Statements available through 2026-10-14. Industry snapshot: 2025-12-31 · 5,721 classified issuers.